Cantor Fitzgerald Issues Positive Estimate for BCRX Earnings

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings estimates for BioCryst Pharmaceuticals from $0.27 to $0.45 per share, maintaining an "Overweight" rating with a target price of $20.00.
• BioCryst Pharmaceuticals reported a quarterly earnings per share of $0.15, surpassing analysts' expectations by $0.12 and achieving a revenue increase of 49.5% year-over-year.
• Investment analysts have shown a positive outlook, with nine buy ratings and an average target stock price of $16.70 across various research reports.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, August 5th. Cantor Fitzgerald analyst S. Seedhouse now expects that the biotechnology company will earn $0.45 per share for the year, up from their prior estimate of $0.27. Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% compared to the same quarter last year.

BCRX has been the topic of several other research reports. Wedbush raised their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, June 30th. JPMorgan Chase & Co. upped their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Bank of America upped their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ BCRX traded down $0.19 during trading hours on Thursday, reaching $8.12. The stock had a trading volume of 1,146,039 shares, compared to its average volume of 3,872,148. The firm has a 50-day moving average of $9.32 and a 200-day moving average of $8.77. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -45.09, a PEG ratio of 1.89 and a beta of 1.10. BioCryst Pharmaceuticals has a fifty-two week low of $6.01 and a fifty-two week high of $11.31.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. boosted its stake in BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after acquiring an additional 3,606,566 shares during the last quarter. Millennium Management LLC boosted its position in BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after buying an additional 3,022,769 shares during the period. Eversept Partners LP lifted its position in shares of BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after purchasing an additional 1,444,907 shares during the period. Nuveen LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $10,677,000. Finally, M&G PLC bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $9,414,000. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.